Year: 2015
Type: article
Study design: Observational Study
Abstract: OBJECTIVE: We sought to develop risk scores for the progression from cognitively normal (CN) to mild cognitive impairment (MCI). METHODS: We recruited into a longitudinal cohort study a randomly selected, population-based sample of Olmsted County, MN, residents, aged 70 to 89 years on October 1, 2004. At baseline and subsequent visits, participants were evaluated for demographic, clinical, and neuropsychological measures, and were classified as CN, MCI, or dementia. Using baseline demographic and clinical variables in proportional hazards models, we derived scores that predicted the risk of progressing from CN to MCI. We evaluated the ability of these risk scores to classify participants for MCI risk. RESULTS: Of 1,449 CN participants, 401 (27.7%) developed MCI. A basic model had a C statistic of 0.60 (0.58 for women, 0.62 for men); an augmented model resulted in a C statistic of 0.70 (0.69 for women, 0.71 for men). Both men and women in the highest vs lowest sex-specific quartiles of the augmented model's risk scores had an approximately 7-fold higher risk of developing MCI. Adding APOE ε4 carrier status improved the model (p = 0.002). CONCLUSIONS: We have developed MCI risk scores using variables easily assessable in the clinical setting and that may be useful in routine patient care. Because of variability among populations, validation in independent samples is required. These models may be useful in identifying patients who might benefit from more expensive or invasive diagnostic testing, and can inform clinical trial design. Inclusion of biomarkers or other risk factors may further enhance the models.
Source: Neurology
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Michael J. Fox Foundation for Parkinson's Research, Robert Wood Johnson Foundation, Eli Lilly and Company, Pfizer, Mayo Foundation for Medical Education and Research, Walter S. and Lucienne Driskill Foundation, TauRx Pharmaceuticals, University of Oxford, H. Lundbeck A/S, National Institutes of Health, Genentech, National Institute on Aging, National Heart, Lung, and Blood Institute, National Institute of Mental Health, National Center for Advancing Translational Sciences
Awards: Multimorbidity and Aging: Rochester Epidemiology Project, Aerobic Exercise in Alzheimer's Disease Cognition and Hippocampal Volume Effects, Mayo Clinic Center for Clinical and Translational Science (CCaTS), G3146424788, G3638781909, G3870774570, Alzheimers Disease Patient Registry, G3930010334, Psychiatric Characterization/Mild Cognitive Impairment, Evaluating and Extending Our Hypothetical Model of Alzheimer's Biomarkers, G5484535055, Alzheimer's Disease Neuroimaging Initiative, ARIC Neurocognitive Study (ARIC-NCS) Renewal 2 of 5, Vascular and Inflammatory Predictors of MCI Risk and Progression, Stroke and Cognitive Impairment in Aging Chronic Kidney Disease Patients, Brain Aging and Alzheimer's Biomarker Classification Using Amyloid PET, tau PET, and Neurodegeneration on MRI: Developing the ATN system, G9000122335, G9000338148, Mayo Alzheimer's Disease Research Center
OpenAlex ID: W2130420537
